Radius Health (NASDAQ:RDUS) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.
A number of other research firms also recently commented on RDUS. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Maxim Group reiterated a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Goldman Sachs Group reiterated a “neutral” rating and issued a $45.00 price target on shares of Radius Health in a research note on Friday, October 6th. Jefferies Group reiterated a “hold” rating and issued a $38.00 price target (up from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. Finally, BidaskClub downgraded Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. Radius Health has a consensus rating of “Hold” and a consensus price target of $51.00.
Shares of Radius Health (RDUS) traded down $0.44 during trading on Friday, hitting $27.87. The stock had a trading volume of 702,158 shares, compared to its average volume of 1,059,109. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health has a 12 month low of $24.66 and a 12 month high of $55.30.
In other Radius Health news, major shareholder Growth N. V. Biotech bought 150,000 shares of the business’s stock in a transaction on Thursday, September 14th. The shares were purchased at an average price of $33.45 per share, with a total value of $5,017,500.00. Following the completion of the acquisition, the insider now directly owns 5,448,799 shares of the company’s stock, valued at approximately $182,262,326.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was acquired at an average cost of $26.25 per share, for a total transaction of $1,312,500.00. Following the acquisition, the insider now directly owns 5,698,799 shares of the company’s stock, valued at $149,593,473.75. The disclosure for this purchase can be found here. Insiders purchased 417,678 shares of company stock valued at $13,583,998 over the last quarter. Insiders own 15.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of RDUS. TimesSquare Capital Management LLC lifted its holdings in Radius Health by 184.6% in the third quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock worth $62,080,000 after acquiring an additional 1,044,615 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Radius Health by 18.3% in the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after acquiring an additional 569,300 shares during the last quarter. BB Biotech AG lifted its holdings in Radius Health by 11.0% in the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after acquiring an additional 498,400 shares during the last quarter. RA Capital Management LLC bought a new position in Radius Health in the second quarter worth about $22,486,000. Finally, Point72 Asset Management L.P. bought a new position in Radius Health in the third quarter worth about $17,236,000.
ILLEGAL ACTIVITY WARNING: This news story was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/12/02/radius-health-rdus-rating-increased-to-sell-at-valuengine.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.